Long-term clinical outcomes of valsartan in patients with a systemic right ventricle: Follow-up of a multicenter randomized controlled trial

In the VAL-SERVE (Valsartan in Systemic Right Ventricle) trial, three-year valsartan treatment improved systemic ventricular function only in symptomatic patients with congenitally or with an atrial switch corrected transposition of the great arteries. The aim of the current study was to investigate the longer-term clinical outcomes after valsartan treatment.

Source: International Journal of Cardiology - November 10, 2018 Category: Cardiology Authors: Alexandra C. van Dissel, Michiel M. Winter, Teun van der Bom, Hubert W. Vliegen, Arie P.J. van Dijk, Petronella G. Pieper, Gert-Jan T. Sieswerda, Jolien W. Roos-Hesselink, Aeilko H. Zwinderman, Barbara J.M. Mulder, Berto J. Bouma Tags: Short communication Source Type: research